Biotechs universally share one mission. The industry aims to prevent or cure diseases to sustain a higher life expectancy. If a biotech successfully achieves its mission, humankind, the patients suffering, and investors all experience euphoria. However, if a biotech fails to develop a viable drug then the nightmarish scenario of people suffering continues.… Read more
Gilead prepared to surge after FDA approval of COVID-19 treatment Remdesivir
Trump announced on Friday that the US Food and Drug Administration has cleared the emergency use of Remdesivir as a COVID-19 treatment. Gilead Sciences (NASDAQ:GILD) will play a vital role in producing 1.5 million doses for patients across the US suffering critical complications from COVID-19. The now infamous Remdesivir has made headlines over the past month, as speculators look to cash in on the drugs anti-viral capabilities.… Read more
How Gilead drove a US rally based on optimism.
The Dow Jones rallied upwards of 700 points on Friday as Gilead’s (NASDAQ:GILD) “Wonder Drug” has shown promising results according to a Chicago University source. The video of Infectious Disease Professor Kathleen Mullane, goes into some detail over the success of Remdesivir in recent trials with patients reporting fast recoveries from COVID-19.… Read more
Gilead Sciences wonder drug showing promise in the COVID-19 battle
Gilead Sciences (NASDAQ:GILD) has made promising progress in the treatment of COVID-19 with their drug Remdesivir. The US Bio-tech giant conducted a trial with 53 patients with COVID-19 in the US, Canada and Europe. All 53 patients were considered to have severe complications due to the virus, all needing respiratory support.… Read more